Quality of life in patients with multiple sclerosis

Karatepe, Altınay Göksel; Kaya, Taciser; Günaydn, Rezzan; Demirhan, Aylin; Çe, Plnar; Gedizlioğlu, Muhteşem

doi:10.1097/mrr.0b013e32834ad479

Cited by 84 publications

(34 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While studies have highlighted the importance of psycho-social issues in determining QOL in MS [13, 14], particularly depression and fatigue [15, 16], there has been little research on associations of lifestyle and socio-demographic factors with physical and mental QOL. Potentially determining these associations may allow clinicians to provide evidence-based advice to people with MS on the relative importance of modifiable lifestyle risk factors that should be prioritized for optimal QOL.…”

Section: Introductionmentioning

confidence: 99%

Lifestyle, medication and socio-demographic determinants of mental and physical health-related quality of life in people with multiple sclerosis

et al. 2016

View full text Add to dashboard Cite

BackgroundHealth-related quality of life (QOL) is a key outcome for people with multiple sclerosis (MS). While modifiable lifestyle factors, like smoking, physical activity and vitamin D, have strong associations with development and progression of MS, few studies have examined such associations with QOL.MethodsUsing patient-reported data from 2312 people with MS from 54 countries, regression models explored associations of socio-demographic, therapeutic and lifestyle factors with QOL, using the Multiple Sclerosis Quality of Life-54 (MSQOL-54).ResultsParticipants were on average 45.6 years old, 82.4% women, mostly partnered (74.1%), with a university degree (59.5%). Controlling for socio-demographic factors and disability, factors associated with better physical health composite (PHC) (on a 100 point scale) were: moderate and high physical activity compared to low (5.9 [95% confidence interval: 4.2, 7.6] and 9.9 [CI: 8.1, 11.6] points higher score respectively); non-smoking compared to current smoking (4.6 points [CI: 2.4, 6.7]); better diet (per 10 points on the 100 point Diet Habits Questionnaire scale (DHQ) 1.6 points [CI: 1.0, 2.2] points); normal body mass index (BMI) versus overweight or obese (2.1 points [CI: 0.4, 3.7] and 2.4 points [CI: 0.5, 4.3]); fewer comorbidities (4.4 points [CI: 3.9, 4.9]); and not taking a disease-modifying drug (DMD) (2.1 points [CI: 0.7, 3.4]).Better mental health composite (MHC) determinants were: moderate and high physical activity compared to low (4.0 points [CI: 2.0, 6.0] and 5.7 points [CI: 3.5, 8.0]); non-smoking compared to current (6.7 points [CI: 4.1, 9.3]); better diet (2.8 points [CI: 1.9, 3.5]); normal BMI versus overweight or obese (3.1 points [CI: 1.1, 5.1] and 3.5 points [CI: 1.3, 5.7]); meditating regularly (2.2 points [CI: 0.2, 4.2]); and no DMD use (2.9 points [CI: 1.3, 4.6]).ConclusionsWhile causality cannot be concluded from cross-sectional data, the associations between modifiable lifestyle factors and QOL suggest significant potential for secondary prevention of the known deterioration of QOL for people with MS through lifestyle risk factor modification.Electronic supplementary materialThe online version of this article (doi:10.1186/s12883-016-0763-4) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Lifestyle, medication and socio-demographic determinants of mental and physical health-related quality of life in people with multiple sclerosis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Subjects performed knee extension exercise on a weight stack machine (Nevada Pro-T, BH Fitness; Vitoria-Gasteiz, Spain) twice per week for 12 wk, with at least 48 h of rest between sessions. The load (40%-70% of MVIC), number of sets (3)(4), and number of repetitions (4-10) were adapted across the training period ( Table 1). The percentage of load during the training period was calculated based on MVIC data obtained at baseline.…”

Section: Muscle Power Trainingmentioning

confidence: 99%

“…Patients with multiple sclerosis (MS) experience a range of symptoms related to mobility restrictions in the lower limbs that often result in impaired mobility [1] and high numbers of falls [2], which may lead to a reduction in their physical activity [3] and a lowering of their quality of life [4]. These symptoms are related to neuromuscular disorders such as impaired muscle strength [5][6] and muscle weakness in the lower limbs [7].…”

Section: Introductionmentioning

confidence: 99%

Effects of high-speed power training on muscle strength and power in patients with multiple sclerosis

et al. 2016

View full text Add to dashboard Cite

Abstract-This study examined the effects of a high-speed power training program in peak muscle power and maximal voluntary isometric contraction (MVIC) of knee extensors in patients with relapsing-remitting multiple sclerosis (MS). Forty patients, 20 women (age 42.8 +/-10.3 yr) and 20 men (age 44.0 +/-8.7 yr) diagnosed with relapsing-remitting MS were randomly assigned, with respect to sex, to either an exercise group or a control group. Participants from the exercise group performed 12 wk of supervised muscle power training of knee extensors. All subjects were tested for MVIC and peak muscle power at baseline and after the training intervention. A strain gauge was used to measure the MVIC, and peak muscle power was assessed with a linear encoder at five relative loads. The training-related effects were assessed using a t-test. The results showed no significant changes in the control group from baseline to postintervention evaluation. In contrast, the exercise group significantly increased MVIC (10.8%; p < 0.05) and muscle power at 40,50, 60, 70, and 80% of the MVIC by 21.8, 14.5, 17.3, 19.4,and 22.3%, respectively (p < 0.01), after the training. These findings suggest that 12 wk of high-speed power training improve both MVIC and muscle power at five different loads in patients with relapsing-remitting MS.

show abstract

“…The rapid anti-fatigue effects of ketamine and the consequential development of an effective long-term anti-fatigue treatment would greatly reduce or eliminate the daily physical and social interferences of fatigue at home and in the workplace, which are often reported by patients with cancer-related fatigue or with chronic fatigue syndrome (Bennet et al, 2007). On a broader scale, these fatigue interventions could address related economic issues, allowing individuals to return to work and maintain productivity, enhancing overall quality of life (Sabes-Figuera et al, 2010; Göksel Karatepe et al, 2011). …”

Section: Discussionmentioning

confidence: 99%

An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder

Saligan

Luckenbaugh

Slonena

et al. 2016

Journal of Affective Disorders

View full text Add to dashboard Cite

Background Fatigue is a multidimensional condition that is difficult to treat with standard monoaminergic antidepressants. Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist produces rapid and robust improvements in depressive symptoms in treatment-resistant depression. However, there is a dearth of literature examining the anti-fatigue effects of ketamine. We hypothesize that ketamine will rapidly improve fatigue symptoms in treatment-resistant depressed patients. Methods This is an exploratory analysis of data obtained from two double-blind, randomized, placebo-controlled, crossover trials. A total of 36 participants with treatment-resistant bipolar I or II disorder in a depressive episode (maintained on therapeutic levels of lithium or valproate) received a single infusion of ketamine hydrochloride intravenously (0.5mg/kg over 40 minutes) or placebo. A post-hoc analysis compared fatigue scores on ketamine vs. placebo at 10 time points from baseline through 14 days post-treatment using the National Institute of Health-Brief Fatigue Inventory. Results A linear mixed model showed that ketamine significantly lowered fatigue scores compared to placebo from 40 minutes post-treatment to Day 14 with the exception of Day 7. The largest difference in anti-fatigue effects between placebo and ketamine was at day 2 (d=.58, p < .05). The effect remained significant after controlling for changes in non-fatigue depressive symptoms. Limitation The retrospective nature and a small sample size are study limitations. Conclusions Ketamine rapidly improved fatigue relative to placebo in a group of individuals with treatment-resistant bipolar depression. NMDAR is a glutamate receptor; hence, glutamate may represent a valuable target to study the clinical efficacy of new anti-fatigue approaches in multiple disorders.

show abstract

Quality of life in patients with multiple sclerosis

Cited by 84 publications

References 94 publications

Lifestyle, medication and socio-demographic determinants of mental and physical health-related quality of life in people with multiple sclerosis

Lifestyle, medication and socio-demographic determinants of mental and physical health-related quality of life in people with multiple sclerosis

Effects of high-speed power training on muscle strength and power in patients with multiple sclerosis

An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder

Contact Info

Product

Resources

About